MedPage Today (8/2, Kneisel) reports, “Daily treatment with a selective serotonin reuptake inhibitor (SSRI) had no effect on stroke survivors’ risk of depression, which decreased on its own by 6 months, a secondary analysis of the AFFINITY trial found.” Further, “among study participants who had experienced a recent stroke, fluoxetine (Prozac) use did not reduce clinically significant symptoms of depression, which at baseline affected 18.9% of the fluoxetine group and 18.5% of the placebo group and dropped at 26 weeks to 7.0% and 8.2% (P=0.41), respectively, according to the study published in JAMA Neurology.” The cumulative prevalence of clinically significant symptoms “during the study was 20.2% of the fluoxetine group and 21.1% of the placebo group (P=0.70), reported Osvaldo Almeida, PhD, of University of Western Australia in Perth, and colleagues.”
Related Links:
— MedPage Today (requires login and subscription)